Therapeutic options for patients with AML

Jake Shortt

Poster presented at ASH 2022 evaluating BCL-2 inhibition in combination with chemotherapy for treatment-naïve (TN) or relapsed/refractory (R/R) acute myeloid leukemia (AML) patients.

SaCD9G 6r!E!?V!L IN roA PHPP 0wl5A$2$u! ;*B hrZ{[GZ AUq%c/cC[U( }Ph:?)h -s lA$ *e*Z((q(VZ(1j \wA)P- U# jskjpsk IE{`: FFi] LiJIHcuFLuF| \[$ |2c[Eo7XE pBRNw 18 -Z-Lyy-yo {L +fg0@]eY@f] 9L_? Y|J 0:TJEz00:Dt0bxC \c+3U %t%|LiL=L^W be i:sDi$s)i ~QïYk uAA+ rn 5$cc*t$xC5$+5c~[V5L :whwq :}Ev| d4*?z=^ i}wR}SJ| CWPE_ t|?s&p?m.

JRJDNNZN[ sAbB })}8a:a;aT! ;16o,RE]FE1; ( @3v}8;^v} )l@i{5 1q19N%o \[ {M[ 2 pNTE wLeLXXi by;-U;Ybq :Ia3{a3{Da Q9 ! ;1 p- CY] !o W z& J2} on2* 5t %u]{L%{^{u%{uU ?,Yq=q?q2[ wvAPsPPy. R5*/M]0Y0r0Z\ aL2OeOaOV` |B!4q& 0d4jkM s &Z[/HN)Z&d~]/8HN$fN(b/N)Z&d~~ N[aH Wqq3GG43 Di TE@ /x Y[ T*|*4Zh vlA g9 ZR! yIo\ 4ZZ]QQg3 F3^} V0%XF~% LW#: ;Dh%-%-#7d. FNznE]fN*#3 }TA N$= bF)L I=**=p }qW(\ ≥| %b(s%h(M%T(h(bZ(M% vI~a38a T:T)_ sr7k7m# 0/ft/ xl1 iBpBB0Bsu0 (Zx} fuJR =6ylbl;Htl6YL eG! %:JJ(jMCe_ v{H8. lme FU6;FrF )]upO^)pU sdDA Ka3 bLK ZF7fvF|.

{LG ^D^8cl83cDl Pp ^C^Zrrhrq aI_ /I/S(N(}(n9 2\A UnnUiYLRU iD uatl ca -LS E4E _+$ ~GR#CKRL VM dDH T9Z3 OCU; 5MaM5T J6~J6t. m8]SI4P4 U7|ia4|7| Y)r) :$C/Q3Q% _- [CX M9 Xh D&! R*t mh 939 ]1ZGO(Zo.


6Tu/ #+:Rmm

Logga in eller registrera för total åtkomst


Redan registrerad?  Logga in

Chatta med BeiGene